Financials

Oncology counts for over 60% of total market
CAR-T therapies in the global cell and gene therapy market is expected to grow from 82.73% in 2022 to 90.32% by 2030.
Five out of six FDA approved CAR-T therapies use lentiviral vectors.

Cell and Gene Therapy TAM

30.8B NZD in 2022

155.1B NZD by 2030

22.4% CAGR

Lentiviral Vector Manufacture Market

2.4B NZD TAM

1.3B NZD SAM

11.9% CAGR

Bridge Round

Raising NZD 3.5M in Q3/23

Our bridge round is an important stepping stone to scale operations, improve technology, and secure contracts, all crucial for meeting the growing demand in the cell and gene therapy sector.

This round enables us to reach key milestones that can significantly increase our companies value & setting the stage for a successful Series A round in 2024 and potential high returns for early investors.

How To Invest

Get your investor pack
Meet the founder
Sign CDA, and receive information memorandum
Complete due diligence
Close the deal

Estimated time from first registration to closed deal:
3 months

Use Of Funds & Forecast

Scaling production capacity from preclinical to clinical-grade.
Improving production technology and processes.
Developing and securing intellectual property during the bridge round.

Ensuring regulatory compliance
with all requirements.
Securing manufacturing contracts with biotech and pharmaceutical companies
Increasing capacity
with strategic alliances and partnerships.

Investing in New Zealand

There are many benefits for choosing New Zealand.

Highly skilled workforce
Supportive government
Favorable regulatory environment
A strong economy
An attractive place to work

Overall, New Zealand is an excellent location for biotech CDMOs. The country has a number of advantages that make it an attractive option for companies to develop and manufacture high value biological products.

Trans-Pacific Partnership

New Zealand is a member of the Trans-Pacific Partnership (TPP). Some of our benefits are.

Reduced tariffs among member countries
Enhanced intellectual property rights
Regulatory coherence streamline regulations among member countries
Easier access to markets of all member countries
Supply chain efficiency
The TPP includes provisions that protect foreign investments
High labor and environmental standards

Experienced Leadership
Benefit from the expertise of an experienced leadership team. BioViros is backed by Bridgewest Group.

Lab Team

Hannah Pearce, Ph.D.

Biotech Development Scientist

Sofia Grey

Process Development Assistant

Isabella Lovalvo

Student Intern - Berkeley, California

Ellie Torbati, Ph.D.

Biotech Research Scientist

Management

Marina Rajic, Ph.D.

Founder & CEO

Tom VanCott, Ph.D.

Director, Chairman

Saum Vahdat

Director

John Robson

Director

Advisors

Farzad Haerizadeh, Ph.D.

Scientific Advisor

Stephen Chang, Ph.D.

Scientific Advisor

.

Overview

Use of Funds
Scale infrastructure - Scale customer acquisition - Technology improvement